Overall Survival Results From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan vs Treatment of Physician’s Choice in Patients With HR+/HER2– Metastatic Breast Cancer
Dr. Hope Rugo reviews updates to data from the TROPiCS-02 trial that were recently presented at ESMO Congress 2022 and speaks to clinical implications of these data.